Companies › Medipost
3 active drug programs in 4 registered trials: 3 Phase 2, 1 Phase 3; Immunology, Other; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CARTISTEM® Allogeneic human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) combined | – | Phase 3 | Knee Cartilage Defects | Jun 2029 |
| SMUP-IA-01 (low-dose) Human umbilical cord blood-derived mesenchymal stem cells | – | Phase 2 | Knee Osteoarthritis | Mar 2027 |
| PNEUMOSTEM® Human umbilical cord blood-derived mesenchymal stem cells | – | Phase 2 | Bronchopulmonary Dysplasia | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06798727 | SMUP-IA-01 (low-dose) | Phase 2 | Knee Osteoarthritis | Immunology | Mar 2027 |
| NCT06798727 | SMUP-IA-01 (low-dose) | Phase 2 | Knee Osteoarthritis | Immunology | Mar 2027 |
| NCT04003857 | PNEUMOSTEM® | Phase 2 | Bronchopulmonary Dysplasia | Other | Jun 2027 |
| NCT07339111 | CARTISTEM® | Phase 3 | Knee Cartilage Defects | Immunology | Jun 2029 |
No annotated target.
–
Nature Cell Throne Biotechnologies Cellcolabs Clinical SPV EHL Bio TBF Genie Tissulaire
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.